Genelabs Technologies' Unattributed VC - II Round

Genelabs Technologies raised a round of funding on February 19, 2007.

is discovering compounds that selectively inhibit replication of the hepatitis C virus, and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while als…

Articles about Genelabs Technologies' Unattributed VC - II Round: